Skip to main content

Pediatric Rheum

COVID-19 Risks in Pregnant Women

Sep 17, 2020

There has been little science or evidence regarding the effects of COVID-19 infection on pregnancy and vice versa; and now the recent MMWR addresses the subject with two new reports

Read Article

ACR 2020 Reproductive Guidelines - Contraception & Counseling

Sep 08, 2020

The American College of Rheumatology established a guidelines committee that consisted of both patients, rheumatologists and maternal-fetal health experts. After a a systematic review of the medical literature regarding contraception, assisted reproductive technology, fertility preservation,

Read Article

COVID and the Multisystem Inflammatory Syndrome in Children

Aug 31, 2020

Lancet Infectious Disease has reviewed the epidemiology, causes, clinical features, and current treatment for the multisystem inflammatory syndrome in children (MIS-C) and adolescents associated with COVID-19, noting severe organ damage can occur pediatric COVID-19 patients who are severely

Read Article

RheumNow Podcast – Rheum Lives Matter (8.28.20)

Aug 28, 2020

Dr. Jack Cush reviews the news and journal articles from the past week. Of mice and men in cartilage, the efficacy of JAK inhibitors in patients who are having skin problems, nrAxSpa has its own diagnostic code, metformin, talking about Back Talk, plus so much more.

Read Article

Treatments Differ Across Centers in Systemic JIA

Aug 26, 2020

Significant variations were seen across hospitals in the treatment of children admitted with new-onset systemic juvenile idiopathic arthritis (JIA), despite increasing evidence of the efficacy of biologics and the hazards of extended glucocorticoid exposure, a retrospective cohort study found

Read Article

Canakinumab Tapering in Still's Disease

Aug 20, 2020

You can reduce - but not stop - canakinumab therapy in patients who are in complete clinical remission in children with systemic juvenile idiopathic arthritis.

Read Article

RheumNow Podcast – Why Do We Love Rheumatology Fellows? (8.7.20)

Aug 06, 2020

Dr. Jack Cush reviews why we all love our rheumatology fellows and our best advice for them stemming from these articles.

Read Article
EU has approved Secukinumab (Cosentyx) for use in pediatric plaque psoriasis - moderate-to-severe psoriasis affects more than 350,000 children worldwide. Approval is based on 2 phase 2 wo international in children 6 to <18 years.

Dr. John Cush RheumNow ( View Tweet)

Aug 05, 2020

RheumNow Podcast - Top 13 Rheumatology Centers (7-31-20)

Jul 31, 2020

Dr. Jack Cush reviews the news and TOP 13 list of Best Rheumatology Hospitals.

Read Article
Down syndrome-associated arthritis (DA) presents as a seronegative erosive polyarthritis. Besides an Avg 19-month delay in Dx, most are treated same as JIA but JIA agents are often poorly tolerated & less effective in DA.

Dr. John Cush RheumNow ( View Tweet)

Jul 29, 2020
French cohort analysis of 104 kids taking Tocilizumab (mostly for Stills dz or polyJIA) shows 25% with serious AE (15.3/100 PY), mostly seriou infections or infusion reactions. at TCZ initiation.

Dr. John Cush RheumNow ( View Tweet)

Jul 27, 2020
Belimumab FDA approved in kids (same dose 10mg/kg/IV) based on PLUTO trial - 93 SLE pts Rx w/ BEL or PBO. By wk 52, BEL had more SRI4 responders (52.8% vs 43.6%; OR 1.49;95% CI 0.64 to 3.46), more PRINTO/ACR 30 or 50 w/ stable PK.

Dr. John Cush RheumNow ( View Tweet)

Jul 24, 2020

RheumNow Podcast – COVID-19 Responds to Steroids (7.24.20)

Jul 24, 2020

Dr. Jack Cush reviews the News and Journal Reports from the past week on

Read Article
Here's our experience at @BostonChildrens in managing patients with MIS-C, as well as how to distinguish these patients from those with #kawasakidisease --> Just published in @jclinicalinvest #COVID19
Jonathan Hausmann MD hausmannMD ( View Tweet)
Jul 23, 2020

Growing Risk of COVID Among Adolescents

Jul 13, 2020

The risk COVID-19 infection and mortality in the U.S. has been closely correlated with increasing age. However, recent data suggests that young adults (aged 18–25 years) have shown an increasing risk of COVID-19 infection since the pandemic began in March 2020.

Analysis of young

Read Article

ICYMI: The Nine Lives of Hydroxychloroquine (Updated)

Hydroxychloroquine is one of many medications frequently used in rheumatology practice. Its remarkable versatility is attested by its routine use in lupus, in patients with an autoimmune coagulopathy, in patients with rheumatoid arthritis, as well as in those with a low-level inflammatory

Read Article

COVID's Multisystem Inflammatory Syndrome in Children

Jun 30, 2020

Two recent reports further characterize the newly described, Kawasaki-like,  syndrome affecting children with COVID-19 infections.

The NEJM describes the childhood syndrome as having Kawasaki’s disease, fever, toxic shock syndrome, acute abdominal conditions, and encephalopathy; hence the label

Read Article
Now with ~1,000 children and adolescents with multi-inflammatory syndrome in children (MIS-C), it can be considered a new disease. Today new @NEJM reports and an editorial on its status. I've made a summary of some key points to start
Eric Topol EricTopol ( View Tweet)
Jun 29, 2020
The CHMP of the European Medicines Agency has recommended the label expansion of IL-17 inhibitor, Cosentyx (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in children and adolescents aged 6-18 years.

Dr. John Cush RheumNow ( View Tweet)

Jun 29, 2020
Global prevalence of juvenile idiopathic arthritis is ~ 2,069,246 < 16 year olds compared with a prevalence of ~ 206,931 < 16 year olds with juvenile SLE. JIA is 10 times more prevalent than lupus in children < 16yrs.

Dr. John Cush RheumNow ( View Tweet)

Jun 28, 2020

ACR Outlines Best Practices for Kids With MIS-C

Jun 25, 2020

Multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19 infection has both similarities and differences with Kawasaki disease, and requires distinct clinical management, according to draft guidance from the American College of Rheumatology (ACR).

Age, symptoms,

Read Article

RheumNow Podcast – Enough Already with Weaning (6.19.20)

Jun 19, 2020

Dr. Jack Cush reviews the news and journal reports from the past week on

Read Article

Canakinumab First FDA-Approved Therapy for Adult-Onset Still's Disease

Jun 17, 2020

Yesterday, the FDA approved canakinumab (Ilaris) as treatment for adult-onset Still's disease (AOSD), the first ever FDA approved drug for AOSD.

Canakinumab, an interleukin-1 inhibitor, was FDA approved in 2013 for use children (aged 2 years and older) with systemic juvenile idiopathic

Read Article

Day 3 - Top 5 from EULAR 2020

Jun 10, 2020

These were my top abstracts from Thursday, 4th of June at EULAR 2020:

Read Article
#EULAR2020 panel on #COVID19 spec. situatns: 1. German regtry: very few preg rheum pts w/CV19; cases mild. 2. No info how CV19 affects APS 3. Very few ped rheum cases of CV19- cases mild; outcomes sim to gen peds pop 4.
Jun 05, 2020